Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PYRNASDAQ:SGMTNASDAQ:TSVTNASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePYRPyroGenesis Canada$0.38$0.38$0.26▼$1.30$67.96M0.747,701 shs29,889 shsSGMTSagimet Biosciences$7.40-10.5%$3.65$1.73▼$9.60$227.00M2.211.04 million shs3.84 million shsTSVT2seventy bio$5.00$4.99$2.29▼$5.30$266.15M1.04639,211 shsN/AVNDAVanda Pharmaceuticals$4.58+1.6%$4.32$3.81▼$6.63$269.92M0.66637,265 shs268,499 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePYRPyroGenesis Canada0.00%0.00%0.00%0.00%0.00%SGMTSagimet Biosciences-10.52%+38.84%+129.81%+92.21%+78.74%TSVT2seventy bio0.00%0.00%0.00%+0.81%+26.58%VNDAVanda Pharmaceuticals+1.55%-0.22%+10.10%-8.22%-26.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPYRPyroGenesis CanadaN/AN/AN/AN/AN/AN/AN/AN/ASGMTSagimet Biosciences2.3579 of 5 stars3.42.00.00.03.12.50.0TSVT2seventy bioN/AN/AN/AN/AN/AN/AN/AN/AVNDAVanda Pharmaceuticals4.6169 of 5 stars3.82.00.04.23.23.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePYRPyroGenesis Canada 0.00N/AN/AN/ASGMTSagimet Biosciences 2.83Moderate Buy$23.17213.06% UpsideTSVT2seventy bio 2.00Hold$5.00N/AVNDAVanda Pharmaceuticals 3.50Strong Buy$16.50260.26% UpsideCurrent Analyst Ratings BreakdownLatest PYR, VNDA, TSVT, and SGMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025SGMTSagimet BiosciencesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $27.005/14/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$13.005/13/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/10/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)5/7/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/24/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)4/8/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)4/1/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/22/2025TSVT2seventy bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPYRPyroGenesis Canada$14.63M4.65N/AN/A$0.07 per share5.43SGMTSagimet Biosciences$2M113.50N/AN/A$3.98 per share1.86TSVT2seventy bio$48.37M5.50N/AN/A$5.04 per share0.99VNDAVanda Pharmaceuticals$201.35M1.34N/AN/A$9.23 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePYRPyroGenesis Canada-$24.74M-$0.11N/A∞N/A-233.18%-194.66%-68.91%N/ASGMTSagimet Biosciences-$27.88M-$1.76N/AN/AN/AN/A-23.63%-22.91%8/13/2025 (Estimated)TSVT2seventy bio-$217.57M-$0.10N/AN/AN/A-207.25%-53.65%-23.67%8/6/2025 (Estimated)VNDAVanda Pharmaceuticals-$18.90M-$0.75N/AN/AN/A-9.51%-3.49%-2.90%7/30/2025 (Estimated)Latest PYR, VNDA, TSVT, and SGMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SGMTSagimet Biosciences-$0.79-$0.56+$0.23-$0.56N/AN/A5/7/2025Q1 2025TSVT2seventy bio-$0.10$0.01+$0.11$0.01$13.96 million$22.94 million5/7/2025Q1 2025VNDAVanda Pharmaceuticals-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million3/25/2025Q4 2024TSVT2seventy bio-$0.23-$0.31-$0.08-$0.37$12.84 million$2.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPYRPyroGenesis CanadaN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ATSVT2seventy bioN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPYRPyroGenesis Canada0.260.860.78SGMTSagimet BiosciencesN/A38.4138.41TSVT2seventy bioN/A4.954.95VNDAVanda PharmaceuticalsN/A4.394.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPYRPyroGenesis Canada0.41%SGMTSagimet Biosciences87.86%TSVT2seventy bio93.90%VNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipPYRPyroGenesis Canada47.68%SGMTSagimet Biosciences14.70%TSVT2seventy bio7.20%VNDAVanda Pharmaceuticals10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePYRPyroGenesis Canada2,020178.88 million93.59 millionNot OptionableSGMTSagimet Biosciences830.68 million25.28 millionOptionableTSVT2seventy bio44053.23 million47.87 millionOptionableVNDAVanda Pharmaceuticals29058.93 million53.13 millionOptionablePYR, VNDA, TSVT, and SGMT HeadlinesRecent News About These CompaniesVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells $32,130.00 in StockJune 17 at 4:15 AM | marketbeat.comInsider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharmaceuticals Inc (VNDA)June 17 at 12:19 AM | gurufocus.comVanda Pharmaceuticals (NASDAQ:VNDA) Upgraded by Wall Street Zen to "Hold" RatingJune 15 at 4:13 AM | americanbankingnews.comVanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to Hold at Wall Street ZenJune 14 at 2:16 AM | marketbeat.comCantor Fitzgerald Predicts VNDA FY2026 EarningsJune 13, 2025 | americanbankingnews.comBrokers Issue Forecasts for VNDA FY2026 EarningsJune 11, 2025 | marketbeat.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 10, 2025 | finanznachrichten.deVanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 10, 2025 | prnewswire.comJane Street Group LLC Decreases Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)June 8, 2025 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Purchased by Two Sigma Investments LPJune 7, 2025 | marketbeat.comMillennium Management LLC Buys 269,183 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)June 1, 2025 | marketbeat.comVanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual MeetingMay 27, 2025 | prnewswire.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Lazard Asset Management LLCMay 26, 2025 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by D. E. Shaw & Co. Inc.May 25, 2025 | marketbeat.comInsider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires 10,000 Shares of StockMay 22, 2025 | insidertrades.comKrensavage Asset Management LLC Cuts Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)May 22, 2025 | marketbeat.comInsider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Purchases 20,000 Shares of StockMay 20, 2025 | insidertrades.comInsider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA)May 20, 2025 | gurufocus.comHC Wainwright Issues Pessimistic Estimate for VNDA EarningsMay 18, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $2.26 Million Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)May 18, 2025 | marketbeat.comVanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit ...May 16, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYR, VNDA, TSVT, and SGMT Company DescriptionsPyroGenesis Canada NASDAQ:PYRPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. It offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. The company also provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montréal, Canada.Sagimet Biosciences NASDAQ:SGMT$7.40 -0.87 (-10.52%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$7.53 +0.13 (+1.76%) As of 04:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.2seventy bio NASDAQ:TSVT$5.00 0.00 (0.00%) As of 05/13/20252seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Vanda Pharmaceuticals NASDAQ:VNDA$4.58 +0.07 (+1.55%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$4.55 -0.03 (-0.63%) As of 06/16/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
